Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Marijuana (cannabis) has been investigated as a potential treatment for colitis, particularly inflammatory bowel diseases (IBD) such as ulcerative colitis and Crohn’s disease. Preclinical studies have shown that cannabinoids, the active compounds in marijuana, can modulate the endocannabinoid system, which plays a role in gut inflammation and motility. Animal models suggest that cannabinoids may reduce inflammation and alleviate symptoms such as abdominal pain and diarrhea. Small-scale human studies and surveys indicate that some patients with colitis report symptom improvement, including enhanced appetite, pain relief, and reduced frequency of diarrhea when using cannabis products.

However, robust clinical evidence is limited. A few randomized controlled trials have been conducted, but sample sizes are typically small and results mixed. Some studies suggest short-term improvement in quality of life and symptoms but do not demonstrate significant effects on objective markers of inflammation or long-term disease outcomes. Major gastroenterological societies acknowledge patient interest in cannabis but note insufficient evidence to recommend its routine use for colitis. Side effects and legal considerations also remain concerns.

In summary, while there is a scientific rationale and preliminary evidence for the use of marijuana in supporting symptom management in colitis, the overall strength of evidence is low (rated 2 out of 5). More rigorous clinical trials are needed to determine its safety and efficacy.

More about Marijuana
More about Colitis

Other ingredients used for Colitis

Other health conditions supported by Marijuana

Products containing Marijuana